• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assay Kits
      • Transcreener® ADP² Kinase Assay Kits
        • Transcreener® ADP2 Assay Kit – FP Readout
        • Transcreener® ADP2 Assay Kit – FI Readout
        • Transcreener® ADP2 Assay Kit – TR-FRET Readout
      • Transcreener® ADO CD73 Assay Kit
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay Kits
        • Transcreener® AMP2/GMP2 FP Assay
        • Transcreener® AMP2/GMP2 Assay Kit – TR-FRET Readout
      • Transcreener® cGAMP cGAS Assay Kits
        • Transcreener® cGAMP Assay Kit – FP Readout
        • Transcreener® cGAMP Assay Kit – TR-FRET Readout
      • Transcreener dAMP Exonuclease Assay Kit
      • Transcreener® EPIGEN SAH Methyltransferase Assay Kit
      • Transcreener® GDP GTPase Assay Kits
        • Transcreener® GDP Assay Kit – FP Readout
        • Transcreener® GDP Assay Kit – FI Readout
        • Transcreener® GDP Assay Kit – TR-FRET Readout
      • Transcreener® UDP² Glycosyltransferase Assay Kits
        • Transcreener® UDP2 Assay Kit – FP Readout
        • Transcreener® UDP2 Assay Kit – FI Readout
        • Transcreener® UDP2 Assay Kit – TR-FRET Readout
      • Transcreener® 2-5A OAS Assay Kit
    • AptaFluor® HTS Assay Kits
      • AptaFluor® SAH Methyltransferase Assay Kit
    • Enzyme Assay Systems
      • TREX1 Assay System
    • Recombinant Enzymes
      • Human cGAS Enzyme
      • Mouse cGAS Enzyme
      • Human DDX3 Enzyme
      • Human OAS1 Enzyme
      • Human TREX1 Enzyme
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • CD38 Assay Services
    • GTPase Profiling Services
    • ATPase Profiling Services
  • Assays by Target
    • Kinase Assays
      • ADK Assays – Application
      • AMPK Assays – Application
      • IKK-beta Assays – Application
      • IRAK4 Assays – Application
      • JAK1 Assays – Application
      • JAK3 Assays – Application
      • MAPK8 Assays – Application
      • PKR Assays – Application
      • RIPK1 Assays – Application
      • RIPK2 Assays – Application
      • TBK1 Assays – Application
    • GTPase Assays
      • GAP Assays – Application
      • GEF Assays – Application
      • KRAS Assays – Application
      • HRAS Assays – Application
      • NRAS Assays – Application
      • RRAS Assays – Application
      • Rac1 Assays – Application
      • RhoA Assays – Application
      • RhoC Assays – Application
      • Cdc42 Assays – Application
      • Ran Assays – Application
    • Methyltransferase Assays
      • EZH2 Assays – Application
      • G9a Assays – Application
      • SET7/9 Assays – Application
      • SET8 Assays – Application
      • PRMT1 Assays – Application
      • PRMT3 Assays – Application
      • PRMT4 Assay – Application
    • STING Pathway Assays
      • cGAS Assay Kits
      • ENPP1 Assays – Application
      • TREX1 Assay System
      • IKK-beta Assays – Application
      • TBK1 Assays – Application
    • Nucleotidase Assays
      • CD38 Assay Services
      • CD39 Assays – Application
      • CD73 Activity Assay Kits
    • Helicase / ATPase Assays
      • DDX3 Assays – Application
      • NSP13 Assays – Application
      • P97 Assays – Application
    • Glycosyltransferase Assays
      • Toxin B Assays – Application
      • GALNT2 Assays – Application
      • GALNT3 Assays – Application
      • BGalT1 Assays – Application
    • Phosphodiesterase Assays
      • PDE3 Assays – Application
      • PDE4 Assays – Application
      • PDE5 Assays – Application
      • PDE7 Assays – Application
    • Ligase and Synthetase Assays
      • SUMO E1 Assays – Application
      • Acyl CoA Synthetase Assays – Application
      • S-Acetyl CoA Synthetase Assays – Application
    • Exonuclease Assays
      • TREX1 Assay System
    • OAS Assays
      • OAS1 Assay Kits
    • Other Enzyme Assays
      • NUDT5 Assays – Application
  • Resources
    • Technical Manuals
    • Transcreener® Assays – Instrument Compatibility
    • Application Notes
    • Posters and Presentations
    • Publications
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
      • Kinases in Innate Immunity
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

Can WRN Helicase Inhibitors Treat MSI-H Cancers?

by Bellbrook Labs / Tuesday, 04 October 2022 / Published in Emerging Targets, HTS Assays, Innate Immunity
Patient With WRN Helicase Syndrome

Over 100 years ago, Otto Werner first characterized a recessive autosomal disorder that caused premature, but largely typical, aging in adults, starting by the 3rd decade and resulting in death by the 6th decade via myocardial infarction or cancer. This disease, now known as Werner syndrome, is caused by specific alterations in the 162 KDa Werner syndrome helicase (WRN) protein. WRN is one of the 5 evolutionarily conserved RecQ helicases found in humans. All human RecQ helicases hydrolyze ATP, unwind double stranded DNA, and are proficient at repairing DNA breaks. WRN alone possesses an exonuclease function. While biochemically similar, each of the 5 RecQ helicases has different substrate preferences and differing sets of protein partners. Deficiency or dysfunction in one of these helicases, therefore, presents separate and distinct phenotypes from the others.1

WRN Structure and Function

WRN consists of an N-terminal exonuclease domain, a helicase domain (consisting of an ATPase and a DNA binding RecQ C-terminal domain), a protein interacting HRDC (helicase-and-ribonuclease D C-terminal) domain, and a nuclear localization signal at the C-terminus. The WRN exonuclease functions in a 3’ to 5’ direction. WRN helicase is capable of unwinding DNA duplexes, possessing at least 10 nucleotides of either a 3’ or 5’ single stranded DNA overhang, and is necessary for localizing to the site of telomere damage. The HRDC domain binds DNA and is important for recruiting WRN to double stranded DNA breaks. The region between the RecQ and HRDC domains endows WRN with the ability to anneal single stranded DNA. Mutations in the C-terminal nuclear signal result in misdirection of WRN to the nucleolus, instead of the nucleus. Almost all the genetic alterations that cause Werner syndrome occur in this region.2

The helicase and exonuclease domains can act alone or in concert to address a variety of DNA substrates, such as double stranded DNA breaks, DNA duplexes, replication forks, Holliday junctions, and G-quadruplexes. WRN can act to stabilize replication forks and effect double stranded DNA break repair via classical non-homologous repair joining, homologous recombination repair, or alternate non-homologous repair joining. WRN associates with elements of the shelterin complex to ensure telomere integrity and acts with PARylated TRF1 to repair oxidative damage to telomeres. In the realms of age-related transcriptional regulation and autophagy, WRN is necessary for transcribing nicotinamide nucleotide adenylyl transferase I and producing cellular NAD+. WRN also induces the production of critical autophagic proteins, such as BECLIN-1, ATG5, and LC3II, that initiate autophagy and impair aging.2

WRN Inhibition as a Therapeutic Target

Deficient or impaired production of WRN, whether through nonsense/missense mutation or promoter methylation, produces accelerated senescence and a greatly increased risk of cancer. Cells from Werner syndrome patients contain abnormally high levels of chromosomal deletions, insertions, rearrangements, and mutations.  Neoplasms that result are predominantly thyroid cancer, melanoma, meningioma, soft tissue sarcomas, leukemia, and osteosarcoma.3

Even though impaired WRN is at the root of oncogenic genomic instability, cancers that lack adequate mismatch repair machinery and enhanced mutation at microsatellite repeats (MSI-H) depend upon active WRN for their survival. Indeed, the helicase function of WRN seems to enable this subset of colorectal, endometrial, and gastric cancers to persist, in spite of their diminished DNA repair ability. The search for effective WRN inhibitors now offers hope to those who suffer from these MSI-H cancers.4

 

References

1.  Lu, H. and Davis, A. J. (2021) Human RecQ Helicases in DNA Double-Strand Break Repair. Front. Cell Dev. Biol., 25. Review. https://doi.org/10.3389/fcell.2021.640755

2.  Gupta, P. et al. (2022) Enigmatic role of WRN-RECQL helicase in DNA repair and its implications in cancer. J Transl Genet Genom 2022;6:147-56. Review. http://dx.doi.org/10.20517/jtgg.2021.60

3.  Li, P. et al. (2015) Methylation of Werner syndrome protein is associated with the occurrence and development of invasive meningioma via the regulation of Myc and p53 expression. Experimental and Therapeutic Medicine, 10:498-502. https://doi.org/10.3892/etm.2015.2519 

4.  Newman, J. A. et al. (2021) Structure of the helicase core of Werner helicase, a key target in microsatellite instability cancers. Life Sci. Alliance. 4(1): e202000795. http://doi.org/10.26508/lsa.202000795

Tagged under: Innate Immunity, kinase assay, WRN Helicase

What you can read next

ADP Detection: It’s not all about kinases
Residence Time Guide
A Guide to Measuring Drug-Target Residence Times with Biochemical Assays
Lupus NIK Inhibitors
Transcreener ADP Assay Enables Evaluation of NIK Inhibitors in Lupus Drug Discovery

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Innate Immunity
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • PARP1 as a Hero vs Villain

    Is PARP1 a Hero or Villain?

    Not counting histones, PARP1 [Poly(ADP-ribose) ...
  • Ongoing Puzzle of c-SRC in Cancer Treatment

    Advancements in The Ongoing Puzzle to Understand c-SRC

    Nearly a half-century ago, sequences from the R...
  • SLAS 2023 Conference Exhibitor Announcement

    SLAS 2023 – HTS Assays and Discovery Services

    BellBrook Labs will exhibit and present posters...
  • BTK's Involved in Systemic lupus erythematosus

    The Challenging Search for BTK Inhibitors

    Bruton’s Tyrosine Kinase (BTK) is a 76kDa...
  • SARM1 Causes Axonal Death

    SARM1 Forefronts Research into Major Neurological Diseases

    SARM1 [Sterile alpha & toll/interleukin rec...

Archives

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2023 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP